Product Details:
Ponaxen-15/45mg-Ponatinib is a type of multi-targeted tyrosine-kinase inhibitor that has been developed by ARIAD Pharmaceuticals. It is primarily used for treating chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). The medicine targets CML with the T315I mutation, which is generally resistant to current therapies such as imatinib. Due to its effectiveness against these tumors, Ponaxen has proven to be a valuable Treatment
Ponaxen-15/45mg-Ponatinib, a type of medication called tyrosine kinase inhibitor, received approval from the US FDA in 2012. The approval was specifically for patients who had chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who were either unable to tolerate or resistant to other treatments. However, the FDA Accelerated Approval program required further studies to be conducted, which were completed in 2016. After the completion of these studies, full approval was granted, and the label was updated. The updated label included patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia as well as Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Additionally, approval was granted for patients who tested positive for T315I and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ponaxen-15/45mg-Ponatinib is a medication that specifically targets BCR-ABL, which is an abnormal tyrosine kinase found in both CML and Ph+ ALL. CML is a condition that is characterized by excessive production of white blood cells due to a genetic abnormality, which can lead to aggressive phases like accelerated or blast crises. Ph+ ALL, on the other hand, is a subtype of acute lymphoblastic leukemia (ALL) that carries the Ph+ chromosome, which produces BCR-ABL. Both of these diseases express the BCR-ABL protein, which makes them potentially susceptible to ponatinib treatment. BCR-ABL is detected in 95% of patients with CML.
Currently, front-line therapies like nilotinib and/or Dasatinib are given to patients, but 22-33% of them discontinue the therapy within two years due to adverse events, treatment failure, and other causes. (3)
Dosage and Administration
The recommended dose and schedule for Ponatinib is 45 mg administered orally once daily. Continue treatment as long as the patient does not show evidence of disease progression or unacceptable toxicity. Ponaxen may be taken with or without food. Tablets should be swallowed whole.
Side Effects of Ponaxen-15/45mg-Ponatinib
Ponaxen-15/45mg-Ponatinib is a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in adults. However, it can cause serious side effects.
The most common side effects of Ponaxen include:
- Skin rash
- Joint pain
- Stomach ache
- Headache
- Constipation
Other side effects of Ponaxen include:
- Increased risk of infection
- Breathlessness and looking pale
- Bruising, bleeding gums, or nosebleeds
Ponaxen can also cause serious side effects, including:
- Blood clots: Ponaxen can increase the risk of blood clots in the arteries and veins. This can lead to serious problems, such as stroke, heart attack, and blood clots in the lungs.
- Arterial occlusion: Ponaxen can cause narrowing of the arteries (arterial occlusion). This can lead to serious problems, such as stroke, heart attack, and gangrene.
- Heart problems: Ponaxen can cause heart problems, such as heart failure, irregular heartbeat, and heart attack.
- Liver damage: Ponaxen can cause liver damage. This can lead to serious problems, such as liver failure. (5)
